NGR-hTNF (antitumor recombinant protein)

NGR-hTNF is an experimental antitumor drug designed to act on tumor blood vessels.[1][2][3] It is currently undergoing Phase III clinical trials [4] for treatment of malignant pleural mesothelioma caused by exposure to asbestos.[5][6][7] NGR-hTNF is also being investigated, alone or in combination with chemotherapy,[8] on four different solid tumors[9][10] in four other randomized Phase II trials.[11]

NGR-hTNF is a recombinant protein derived from the fusion between peptide CNGRCG [12] and human tumor necrosis factor alpha [13] (TNFα).[14][15] Once it has reached the tumor, NGR-hTNF performs its antitumor action.[16] The Phase III (NGR015) [17] clinical trial is in progress in 35 clinical centers in Europe (Italy, UK, Ireland, Poland and Belgium), USA, Canada and Egypt. NGR-hTNF is the only drug being tested in Phase III trials [18] for the treatment of relapsed Mesothelioma, and has been granted Orphan Drug designation both in Europe and USA. [19][20]

References

  1. ↑ "NGR hTNF among the Top 10". http://www.biotechnology-europe.com. External link in |publisher= (help)
  2. ↑ Lorusso D, Scambia G, Amadio G, di Legge A, Pietragalla A, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase A, Bordignon C (Jun 2012). "Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients". British Journal of Cancer. 107 (1): 37–42. doi:10.1038/bjc.2012.233. PMC 3389423Freely accessible. PMID 22644293.
  3. ↑ "MolMed a New Patent on Its Anticancer Drug NGR-hTNF". http://finance.yahoo.com. External link in |publisher= (help)
  4. ↑ "MolMed PhaseIII Trial on NGRhTNF". http://www.biotechnology-europe.com. External link in |publisher= (help)
  5. ↑ Ceresoli GL, Gridelli C, Santoro A (July 2007). "Multidisciplinary treatment". Oncologist. 12: 850–63. doi:10.1634/theoncologist.12-7-850. PMID 17673616.
  6. ↑ "MolMed starts Phase III of NGRhTNF". http://www.mesotheliomacenter.org. External link in |publisher= (help)
  7. ↑ Ceresoli GL, Gridelli C, Santoro A (2007), Multidisciplinary treatment of malignant pleural mesothelioma. Oncologist., pp. 12:850–863
  8. ↑ Curnis F, Sacchi A, Corti A, J Clin Invest (2002b web), Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration, pp. 110:475–482 Check date values in: |date= (help)
  9. ↑ Lorusso D, Scambia G, Amadio G, Di Legge A, Pietragalla A, De Vincenzo R, masciullo V, Di Stefano M, Mangilli G, Citterio G, Mantori M, Lambiase A, Bordignon C (2012-06-26), Phase II study of NGR-hTNF in combination with doxorubicina in relapsed ovarian cancer patients. Br J Cancer, pp. 107(1):37–42
  10. ↑ Gregorc V, De Braud FG, De Pas TM, scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Capio F, Lambiase A, Bordignon C (Apr 2011), "Phase I study of NGR-hTNF,a selective vascular targeting agent, in combination with cisplatin in refractary solid tumors. Clin Cancer Res", Clin. Cancer Res., 17: 107(1):37–42 1;17 (7): 1964–72, doi:10.1158/1078-0432.CCR-10-1376, PMID 21307147
  11. ↑ "MolMed new data ngr htnf". http://www.drugs.com. External link in |publisher= (help)
  12. ↑ "Safety and anticancer activity of low dose regimen of NGR-hTNF" (PDF). www.molmed.com.
  13. ↑ Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000), Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol, pp. 18:1185–1190.
  14. ↑ "Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration". http://www.jci.org/. External link in |publisher= (help)
  15. ↑ Fiers. Biologic therapy with TNF: preclinical studies. In: Company JL, ed. Biologic therapy of cancer: principles and practice, Philadelphia: (ed V De Vita, S Hellman and S Rosenberg (edts))., pp. 1995:295
  16. ↑ Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C (Apr 2011). "Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors". Clinical Cancer Research. 17 (7): 1964–72. doi:10.1158/1078-0432.CCR-10-1376. PMID 21307147.
  17. ↑ "MolMed Completes Enrolment in Pivotal Phase III". http://www.evaluategroup.com/. External link in |publisher= (help)
  18. ↑ "MolMed starts Phase III trial of NGR-hTNF in mesothelioma" (PDF). http://www.molmed.com/. External link in |publisher= (help)
  19. ↑ "US FDA Grants Orphan Status to Mesothelioma Drug". http://www.asbestos.net/. External link in |publisher= (help)
  20. ↑ "MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States". http://finance.yahoo.com/. External link in |publisher= (help)
This article is issued from Wikipedia - version of the 9/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.